surmount 5 tirzepatide ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction Tirzepatide superior to Semaglutide- SURMOUNT-5

The study spanned approximately 20 weeks per patient, including an enrolment visit (V1) conducted within 8 weeks prior to Ramadan, optional intermediate visits (V2.X), and an end-of-follow-up visit (V3) 08 weeks post-Ramadan

Before study initiation, the proportion of patients using a GLP-1 RA was lower than 40% in both cohorts

By Winnie Liu - Last Updated: June 20, 2024 Related Posts Researchers examined how clinicians can support patient self-efficacy throughout their inflammatory bowel disease journey

Beyond potential fatigue, tirzepatide is associated with several well-documented side effects, predominantly affecting the gastrointestinal system